Aetna Stopped Covering Wegovy or Zepbound? What to Do Next

Aetna does not have one universal policy on Wegovy or Zepbound-coverage is set plan-by-plan, and many employer and individual plans moved the drugs to a non-preferred or “excluded” tier in 2026. Start by checking your plan’s current formulary and prior-authorization criteria, then decide whether to file an exception, switch to a covered alternative, or pay cash through a manufacturer or telehealth program. Each path has clear paperwork, deadlines, and cost ranges you can act on today.

• Aetna administers more than 30,000 employer and Marketplace plans, so Wegovy or Zepbound may be covered, restricted, or excluded depending on the contract language.
• Most Aetna commercial plans now require a body-mass index (BMI) of at least 30 kg/m² (27 kg/m² with one weight-related condition) and documented 6-month lifestyle changes before approving a GLP-1.
• A standard formulary appeal must be acknowledged within 72 hours for urgent requests and within 15 days for non-urgent commercial appeals (aetna.com).
• Novo Nordisk lists the self-pay price of Wegovy at $1,349.02 per 4-dose pen pack while LillyDirect prices Zepbound at $1,059 for the same 4-dose supply (novocare.com / lillydirect.com).

What changed with Aetna’s GLP-1 coverage?

Many Aetna commercial and Affordable Care Act (ACA) Marketplace plans reclassified Wegovy and Zepbound as non-preferred specialty drugs in mid-2026, moving them from Tier 3 or Tier 4 to an exclusion list that requires case-by-case prior authorization. The change was largely driven by rising plan spending and new guidance from CVS Caremark, Aetna’s pharmacy benefits manager, which advised employers to exclude weight-loss GLP-1s unless they adopted a strict clinical policy. Members started receiving denial letters citing “plan exclusion” or “non-covered benefit” for National Drug Codes (NDCs) associated with Wegovy and Zepbound.

Medicare and Medicaid plans administered by Aetna follow separate rules. Medicare Part D plans generally do not cover weight-loss drugs, while many state Medicaid programs have not yet added anti-obesity GLP-1s to their preferred drug lists. Always confirm your specific plan type before assuming coverage.

How to confirm your plan’s current status

The fastest way to know whether your claim was denied correctly is to pull three documents and compare them: your plan’s current formulary, the clinical policy bulletin (CPB 114) for anti-obesity medications, and your denial letter.

Step-by-step:

• Download the 2026 formulary: Log in to your Aetna member portal, open “Plan Documents,” and select the 2026 Preferred Drug List. Search for the J-code (J3490) or the NDC of your pen strength to see the tier and any PA symbol.
• Read Clinical Policy Bulletin 114: Aetna’s CPB outlines BMI thresholds, comorbidity requirements, lifestyle documentation, and reauthorization rules (aetna.com).
• Match the denial code: Common denial codes include 75 (Plan Exclusion) and 62 (Clinical Criteria Not Met). The code tells you whether to file a formulary exception or supply additional medical records.
• Call the number on your ID card: Ask the representative whether the drug is “excluded,” “non-preferred with step therapy,” or “covered under medical benefit.” Write down the call reference number.

Why coverage varies across Aetna plans

Aetna underwrites some plans directly but “administrates” most employer plans, meaning the employer decides what the plan will cover and how much cost sharing applies.

Key variables that determine GLP-1 coverage:

• Employer carve-outs: Large self-funded employers often follow CVS Caremark’s recommendation to exclude weight-loss drugs unless the company buys an Obesity Care Management add-on.
• State mandates: Six states now require Marketplace plans to cover at least one FDA-approved weight-loss drug, so Aetna’s ACA formularies in those states list Wegovy as Tier 5 with prior authorization.
• Stop-loss renewal cycle: Employers renegotiate in Q4, so coverage can change on January 1 even if you met criteria last year.
• Specialty carve-out programs: Some plans move GLP-1s to “buy-and-bill” under the medical benefit, shifting the preapproval to a different department.

How to request an exception or appeal a denial

An exception or appeal can overturn a denial when you meet the clinical criteria or when the plan lacks a suitable alternative. Aetna recognizes four levels of review: initial prior authorization, formulary exception, internal appeal, and external review.

Documents that strengthen your case: BMI chart, weight-related diagnosis codes (e.g., E66.01 for morbid obesity), 6-month lifestyle program notes, and a prescriber letter explaining why alternatives failed.

Manufacturer self-pay prices and savings cards

If the appeal will take weeks, compare immediate self-pay paths that keep you on the same brand.

Tip: Mail-order shipping from the manufacturer usually arrives within 2 to 4 days. Ask your prescriber to send the e-prescription directly to the manufacturer’s specialty pharmacy to avoid a second transfer fee.

Other ways to lower out-of-pocket cost

Use these additional tactics to trim your pharmacy bill while you wait for a coverage decision:

• Flexible Spending Account (FSA) dollars: Weight-loss drugs that treat obesity qualify as an IRS-eligible medical expense when prescribed.
• Fill a 90-day script at a specialty pharmacy: Some Aetna plans allow three-month fills after the titration phase, reducing dispensing fees.
• Ask about BMI waiver programs: Aetna occasionally waives the BMI requirement for patients with non-alcoholic steatohepatitis (NASH) or pre-transplant status when documented.
• Compare local cash prices: Use the free Rx.com discount card to see if another pharmacy beats your current cash quote on supplies like syringes or sharps containers.